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(HAM-D). Blood samples were taken at 8:00 to 9:00 am (almost 12 
hours after the drug administration) at 4th week for measurement 
steady-state drug concentrations and genotyping. Genotyping for the 
ABCB1 gene 3435C> T (exon 26) polymorphism was performed by 
PCR/RFLP assays. Serum levels of citalopram were determined by 
high-performance liquid chromatography.
Results: We found statistically significant differences between the 
frequency of C allele for 3435C/T of patients and controls (p= 0.020) 
(Table). The efficacy of citalopram was examined for genotypes in 
2 ways comparisons as responder/nonresponder groups according 
to HAM-D scores at 6th week and also HAM-D scores at 1st, 2nd, 
and 4th weeks. There was no significant difference for 3435C/T 
between the responders and nonresponders (P = 1.000). According 
to 3435C/T genotype HAM-D scores were not statistically significant 
(F = 1.280, P = 0.279).
Table.  Genotype and allele frequencies of ABCB1 3435C/T 
polymorphism in MDD and control groups.
Group Genotype distribution, n (%) Allele frequency, n (%)
C/C C/T T/T C T
MDD (n = 56) 19 (35%) 22 (41%) 13 (24%) 60 (56%) 48 (44%)
Control (n = 70) 8 (11%) 41 (59%) 21 (30%) 57 (41%) 83 (59%)
χ 2= 10.199, df= 2, 
p= 0.006*
χ 2= 5.389, df= 1, 
p= 0.020*
Conclusion: Our results suggested that C3435T polymorphism in 
the ABCB1 gene may be an indicator of the susceptibility to major 
depression but not likely treatment response to citalopram in Turkish 
population.
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Introduction: CYP2D6 differences have already been demonstrated 
within Latin-American populations by the Iberoamerican Network 
of Pharmacogenetic CEIBA Consortium. However, until now, no 
other investigations have been developed within Costa Rica’s popu-
lation, which is of interest becuase this population has a trihybrid 
component ancestry. The present study was aimed to determine the 
frequency of CYP2D6 predicted phenotype within 3 Costa Rican 
groups with different ethnic backgrounds and to describe CYP2D6 
genotypes and allele frequencies compared with other Latin-
American populations.
Patients (or Materials) and Methods: Three hundred eighty-five 
individuals were included in the study (139 Mestizo/CRM, 197 
Amerindians/AM, and 49 Afro-Caribbeans/AC). XL-PCR and real-
time PCR were performed to determine CYP2D6 genotypes. The 
CYP2D6 variant alleles *2, *3, *4, *5, *6, *10, *17, *29, *35 and 
*41 were determined.
Results: The highest frequencies of UMs (10.1%) and PMs 
(10.2%) were found in the CRM and AM population, respec-
tively. Multiplication of active genes (5.4%) were responsible for 
the high frequency of UMs in CRM population, and the pres-
ence of CYP2D6*4 (22.6%) for PMs in AM group. As expected, 
CYP2D6*17 and *29 were higher in AC group, 18.4 and 11.2% 
respectively. However, *10 was lower in the AM population (0.3%).
Conclusion: CYP2D6 predicted phenotypes vary for UMs from 10.1 
to 3.6% and PMs from 10.2 to 1.4%, among 3 Costa Rican groups 
with different ethnic background. In addition, CYP2D6 genotype 
and allele frequencies of the Costa Rican population studied differ 
in comparison to other Latin-American populations.
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Introduction: Losartan has been suggested as a selective probe for 
CYP2C9 metabolic activity. Recently, a single nucleotide polymor-
phism (SNP) IVS8-109A> T linked to SNPs in the 5’-UTR, exon 1 
and intron 1 of the CYP2C9 gene1 has been described in association 
with a higher CYP2C9 losartan metabolic ratio (MR) in healthy 
Swedes.2 The aim of this study was to examine whether there is a 
relationship between the CYP2C9 polymorphism IVS8-109A> T and 
the losartan/E3174 MR, in a previously studied healthy population 
of Ecuadorians.3
Patients (or Materials) and Methods: The CYP2C9 IVS8-109A> T 
polymorphism was analyzed in 161 unrelated Ecuadorian subjects 
using a specific PCR-RFLP method.2 These participants had been 
previously genotyped for CYP2C9 alleles *2, *3, *4, *5 and *6 and 
phenotyped with a single oral dose of 25 mg losartan,3 and all of 
them were CYP2C9*1/*1.
Results: The frequency of the allelic IVS8-109A> T polymorphism 
in this study was 0.23. The urinary losartan/E3174 ratio was sig-
nificantly higher (p = 0.024; Student t test) in subjects with the A/A 
(IVS8-109) genotype (mean [SD], 5.1 [6.6]; n = 95) than in subjects 
with T/T (2.3 [3.7]; n = 8). Present results show that the IVS8-109T 
allele is associated with a lower CYP2C9 MR in this healthy popu-
lation of Ecuadorian subjects, which is in disagreement with previ-
ous findings in healthy Swedes that reported the IVS8-109T allele in 
association with a higher CYP2C9 MR.2
Conclusion: This study shows that the SNP IVS8-109T allele is asso-
ciated with a lower CYP2C9 MR, but further investigations need to 
be carried out to establish a molecular explanation for ultra-rapid 
CYP2C9- catalyzed metabolism.
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